EichorEICHOR
Condition: Relapsed Or Resistant Acute Leukaemias Synced from ClinicalTrials.gov · August 07, 2026

Recruiting studies: Relapsed Or Resistant Acute Leukaemias

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

The Safety and Tolerability of LBS-007 in Patients With Relapsed or Resistant Acute Leukaemias
Phase 1/Phase 2 · 17 location(s) · Lin BioScience, Inc · NCT05756322Fourth-gen CAR T Cells Targeting CD19/CD22 for Highly Resistant B-cell Lymphoma/Leukemia (PMBCL/CNS-BCL).
Phase 1/Phase 2 · 1 location(s) · Essen Biotech · NCT06213636DR-18 to Prevent or Treat Acute Myeloid Leukemia or Myelodysplastic Syndrome Relapse After Hematopoietic Cell Transplant
Phase 1 · 1 location(s) · Fred Hutchinson Cancer Center · NCT06492707
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →
Eichor
Clinical intelligence from public evidence
Use of Eichor is governed by our Terms of Use · Privacy Policy
© 2026 Biomedistats LLC (dba Eichor)

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.